Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Patent
1998-01-20
2000-04-18
Brusca, John S.
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
4353201, 536 235, 536 2372, 4241991, 4242311, C12N 1563, C12N 1512, C12N 1538, A61K 39245
Patent
active
060514280
ABSTRACT:
An autologous vaccine to tumor cells is produced by transducing the tumor cells with a herpes simplex virus amplicon containing the gene for an immunomodulatory protein to provide transient expression of the immunomodulatory protein by the cells. The tumor cells may transduced with the herpes simplex amplicons ex vivo or in vivo. Suitable immunomodulatory proteins include cytokines, for example, interleukins, interferons, and chemokines such as RANTES; intercellular adhesion molecules, for example ICAM-1 and costimulatory factors such as B7.1. The tumor cells may also be transduced with one or more species of amplicon containing genes for two or more different immunomodulatory proteins.
REFERENCES:
Parijs et al. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science vol. 280 pp. 243-248, 1998.
Hellstrom et al. Tumor vaccines-A reality at last? Journal of Immunotherapy vol. 21 pp. 119-126, 1998.
Vieweg et al. considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Investigation vol. 13 pp. 193-201, 1995.
Stevenson Tumor Vaccines FASEB J. vol. 5 pp. 2250-2257, 1991.
Tung, et al., "Rapid Production of Interleukin-2-Secreting Tumor Cells by Herpes Simplex Virus-Mediated Gene Transfer: Implications for Autologous Vaccine Production.", vol. 7, 1996, pp. 2217-2224.
Kutubuddin, et al., "Eradication of preexisting murine tumor using herpes amplicon vectors.", Cancer Gene Therapy vol. 4, No. 6, Nov. 1997--Dec. 1997, p. S26.
Dranoff, et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.", 1993, pp. 3539-3543.
Karpoff, et al., "Prevention of Hepatic Tumor Metastases in Rats with Herpes Viral Vaccines and y-Interferon.", vol. 99, No. 4, Feb. 1997, pp. 799-804.
Vieweg, et al., "Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.", Medline for Cancer Res 54: 1760-1765 (1994).
Iwanuma, et al., "Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.", Medline for Cancer Immunol Immunother 40: 17-23 (1995).
Abe, et al., "Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovires- and retrovirus-medicated genetic transduction." Medline for J Cancer Res Clin Oncol 121: 587-592 (1995).
Federoff Howard
Fong Yuman
Rosenblatt Joseph D.
Brusca John S.
Sloan-Kettering Institute for Cancer Research
University of Rochester
LandOfFree
Rapid production of autologous tumor vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapid production of autologous tumor vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid production of autologous tumor vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2335547